Radiation therapyFDA-approvedSecond-line
Radium-223
How it works
Delivers radiation directly to cancer cells in the bone, killing them and reducing bone pain.
Cancer types
Prostate Cancer— All patients
Efficacy
Radium-223 has been shown to improve overall survival and reduce bone pain in patients with advanced prostate cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Radium-223 in Biochemically Recurrent Prostate Cancer: A Phase 2 Clinical Trial | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy Shows Delayed Survival Benefit in Prostate Cancer | Prostate Cancer | phase-3 | Significant survival benefits were observed after 60 months, with RMST differences of 4.34 months (95% CI, 0.49-8.19, p = 0.03) at 60 months and 6.25 months (95% CI, 1.56-10.95, p = 0.01) at 72 months. | Source → |
| Radium-223 Treatment for Advanced Prostate Cancer | Prostate Cancer | observational | Maximum PSA and ALP declines of ≥ 30% were achieved in 16 (17.2%) and 39 (41.9%) patients, respectively. | Source → |
| Radium-223 Treatment for Prostate Cancer: Long-term Fracture Risk | Prostate Cancer | observational | The overall incidence proportion of fractures reported as adverse events was 7.76% (95% confidence interval [CI] 5.09-11.25%), with a fracture incidence rate of 5.22 patients [with fracture]/100 person-years (PY). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.